Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 0.98 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.98 |
| ▸ | ABL2 | P42684 | 7/20 | 0.98 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.98 |
| ▸ | LYN | P07948 | 3/20 | 0.98 |
| ▸ | SRC | P12931 | 2/20 | 0.98 |
| ▸ | SYK | P43405 | 2/20 | 0.98 |
| ▸ | PLK4 | O00444 | 1/20 | 0.98 |
| ▸ | DDX3X | O00571 | 1/20 | 0.98 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.98 |
| ▸ | CA12 | O43570 | 1/20 | 0.98 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | EGFR | P00533 | 1/20 | 0.98 |
| ▸ | CA1 | P00915 | 1/20 | 0.98 |
| ▸ | CA2 | P00918 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL662077 | 0.99 | ABL1 (0.97) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2236091 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29355523 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3827 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29351601 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1977949 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3138052 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2929858 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1462774 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL529425 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107625773-A | The pharmaceutical composition and its preparation of a kind of imatinib mesylate | 海南锦瑞制药有限公司 | 2018-01-26 | — | — | CN | claimed |
| WO-2013120852-A1 | INTERMEDIATES FOR A NOVEL PROCESS OF PREPARING IMATINIB AND RELATED TYROSINE KINASE INHIBITORS | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2013-08-22 | — | — | WO | claimed |
| CN-109516991-A | A kind of citric acid tropsch imatinib crystal-form compound and preparation method thereof | 山东罗欣药业集团股份有限公司 | 2019-03-26 | — | — | CN | disclosed |
| CN-107625773-A | The pharmaceutical composition and its preparation of a kind of imatinib mesylate | 海南锦瑞制药有限公司 | 2018-01-26 | — | — | CN | disclosed |
| CN-107625773-A | The pharmaceutical composition and its preparation of a kind of imatinib mesylate | 海南锦瑞制药有限公司 | 2018-01-26 | — | — | CN | disclosed |
| WO-2013120852-A1 | INTERMEDIATES FOR A NOVEL PROCESS OF PREPARING IMATINIB AND RELATED TYROSINE KINASE INHIBITORS | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2013-08-22 | — | — | WO | disclosed |